Next Article in Journal
Marek’s Disease Virus Regulates the Ubiquitylome of Chicken CD4+ T Cells to Promote Tumorigenesis
Previous Article in Journal
Single-Domain Antibodies Represent Novel Alternatives to Monoclonal Antibodies as Targeting Agents against the Human Papillomavirus 16 E6 Protein
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
IJMS
Volume 20
Issue 9
10.3390/ijms20092090
ijms-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement thumb_up
...
textsms
...
Open AccessArticle

Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen

by
Nikola Štambuk
1,*,†,
Paško Konjevoda
2,†,
Petra Turčić
3,*,
Hrvoje Šošić
4,
Gorana Aralica
5,6,
Damir Babić
6,7,
Sven Seiwerth
6,7,
Željko Kaštelan
8,
Renata Novak Kujundžić
2,
Piotr Wardega
9,
Jelena Barać Žutelija
10,
Ana Gudelj Gračanin
11 and
Mario Gabričević
12
1
Center for Nuclear Magnetic Resonance, Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia
2
Laboratory for Epigenomics, Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia
3
Department of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Domagojeva 2, HR-10000 Zagreb, Croatia
4
Department of Urology, Clinical Hospital Centre Split, Šoltanska 1, HR-21000 Split, Croatia
5
University Hospital Dubrava, Avenija Gojka Šuška 6, HR-10000 Zagreb, Croatia
6
Department of Pathology, School of Medicine, University of Zagreb, Šalata 10, HR-10000 Zagreb, Croatia
7
Department of Pathology, University Hospital Centre Zagreb, Kišpatićeva 12, HR-10000 Zagreb, Croatia
8
Department of Urology, University Hospital Centre Zagreb, Kišpatićeva 12, HR-10000 Zagreb, Croatia
9
NanoTemper Technologies sp. z o.o., Bobrzynskiego 14, 30-348 Krakow, Poland
10
Clincal Department of Pathology “Ljudevit Jurak”, Clinical Hospital Center “Sestre milosrdnice”, Vinogradska 29, 10000 Zagreb, Croatia
11
Department of Internal Medicine, Division of Clinical Immunology, Allergology and Rheumatology, School of Medicine, University of Zagreb, Dubrava University Hospital, Avenija Gojka Šuška 6, HR-10000 Zagreb, Croatia
12
Department of General and Inorganic Chemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, HR-10000 Zagreb, Croatia
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(9), 2090; https://doi.org/10.3390/ijms20092090
Received: 24 January 2019 / Revised: 5 April 2019 / Accepted: 25 April 2019 / Published: 28 April 2019
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
View Full-Text Download PDF
Browse Figures

Abstract

The purpose of this paper was to outline the development of short peptide targeting of the human prostate specific antigen (hPSA), and to evaluate its effectiveness in staining PSA in human prostate cancer tissue. The targeting of the hPSA antigen by means of antisense peptide AVRDKVG was designed according to a three-step method involving: 1. The selection of the molecular target (hPSA epitope), 2. the modeling of an antisense peptide (paratope) based on the epitope sequence, and 3. the spectroscopic evaluation of sense–antisense peptide binding. We then modified standard hPSA immunohistochemical staining practice by using a biotinylated antisense peptide instead of the standard monoclonal antibody and compared the results of both procedures. Immunochemical testing on human tissue showed the applicability of the antisense peptide technology to human molecular targets. This methodology represents a new approach to deriving peptide ligands and potential lead compounds for the development of novel diagnostic substances, biopharmaceuticals and vaccines. View Full-Text
Keywords: neoplasm; prostate specific antigen; biomarker; antisense peptide; immunohistochemistry; nanomedicine neoplasm; prostate specific antigen; biomarker; antisense peptide; immunohistochemistry; nanomedicine
►▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

SciFeed

Share and Cite

MDPI and ACS Style

Štambuk, N.; Konjevoda, P.; Turčić, P.; Šošić, H.; Aralica, G.; Babić, D.; Seiwerth, S.; Kaštelan, Ž.; Kujundžić, R.N.; Wardega, P.; Žutelija, J.B.; Gračanin, A.G.; Gabričević, M. Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen. Int. J. Mol. Sci. 2019, 20, 2090. https://doi.org/10.3390/ijms20092090

AMA Style

Štambuk N, Konjevoda P, Turčić P, Šošić H, Aralica G, Babić D, Seiwerth S, Kaštelan Ž, Kujundžić RN, Wardega P, Žutelija JB, Gračanin AG, Gabričević M. Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen. International Journal of Molecular Sciences. 2019; 20(9):2090. https://doi.org/10.3390/ijms20092090

Chicago/Turabian Style

Štambuk, Nikola; Konjevoda, Paško; Turčić, Petra; Šošić, Hrvoje; Aralica, Gorana; Babić, Damir; Seiwerth, Sven; Kaštelan, Željko; Kujundžić, Renata N.; Wardega, Piotr; Žutelija, Jelena B.; Gračanin, Ana G.; Gabričević, Mario. 2019. "Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen" Int. J. Mol. Sci. 20, no. 9: 2090. https://doi.org/10.3390/ijms20092090

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop